Mark Kendall: Demo: A needle-free vaccine patch that's safer and way cheaper
Mark Kendall: Un pegat-vacuna sense agulla que és més segur i molt més barat.
Mark Kendall aims to shake up how vaccines are delivered with the Nanopatch. Full bio
Double-click the English transcript below to play the video.
de l'agulla i la xeringa.
fins i tot avui,
this 160-year-old technology.
una tecnologia que té 160 anys.
que més ha incrementat
l'agulla i la xeringa.
of the rollout of vaccines.
per a l'ús de les vacunes.
you probably may have heard of,
may not have heard about.
that I'll tell you about as well.
de la que us parlaré també.
tackle those four problems.
aquests quatre problemes.
work with the skin's immune system.
amb el sistema immunitari de la pell.
is one that's been borrowed
the projections of the Nanopatch
les projeccionsdel Nanopegat
the Nanopatch to the skin as so --
a reuse of the applicator itself.
responses through delivery,
en el subministrament,
de la cadena de fred.
this immunogenicity idea.
la idea d'immunogenicitat.
amb paraules simples,
d'una manera senzilla.
una resposta immunitària,
how to deal with intruders.
com tractar els intrusos.
with the needle and syringe,
is holding back our immune responses;
la resposta immunitària;
la immunitat que és a la pell.
going 10 times deeper as well.
10 vegades més profunda.
have those projections in the skin.
dins de la pell,
una capa exterior de pell morta,
called a Langerhans cell --
cèl·lula de Langerhans.
there's others shown as well
i n'hi ha d'altres
of these particular cells
this thing and designed it to do that,
the dose shown in nanograms.
la dosi en nanograms,
the immune response generated,
the protection threshold.
el llindar de protecció.
is achieved with the needle that's protective,
de la xeringa és protector,
completament diferent.
that works but is too expensive
però que és molt cara,
compared to the needle.
10 dollars down to 10 cents,
de 10 € a 10 cèntims,
within the developing world.
en desenvolupament.
7 million deaths per year,
method for any of those.
that we have with the Nanopatch,
palanca nova del Nanopegat
candidate vaccines over the line.
a estar sobre la línia.
les vacunes d'avui en dia,
conservar la cadena de fred.
a vaccine right from production
des que es produeix
cold chain has fallen over.
de fred s'ha trencat.
in with the needle and syringe
when it's liquid it needs the refrigeration.
el líquid necessita refrigeració.
any loss in activity at all.
cap pèrdua d'activitat.
we have well and truly proven
i m'encanta la ciència.
out, taken it out of the lab
fora del laboratori
journey in an unusual way.
of a developing world country.
de país en desenvolupament.
refrigerators to keep vaccines chilled.
per guardar-hi les vacunes.
many of them are breaking down
moltes s'estan espatllant
where they are required.
world's highest incidence of HPV,
té la major incidència del món de VPH,
cervical cancer [risk factor].
de risc del càncer cervical.
en grans quantitats
the attributes of the Nanopatch,
i tenint el Nanopegat
worked with the Nanopatch,
the world I'd rather be doing.
of being needle-free, pain-free,
sense agulla, sense dolor,
and improving the immunogenicity.
de millorar la immunogenicitat.
ABOUT THE SPEAKER
Mark Kendall - Biomedical engineerMark Kendall aims to shake up how vaccines are delivered with the Nanopatch.
Why you should listen
Looking a bit like a fuzzy computer chip, the Nanopatch uses tiny powder-coated spikes to deliver a small dose of vaccine just under the skin, immunizing a person in about a minute. Made for less than $1, it uses only a fraction of a vaccine dose delivered by traditional syringe method (which was invented in 1853), at the same time eliminating the risk of needle injuries. What’s more, a Nanopatch infused with vaccine is designed to be heat-stable, so it can be transported without refrigeration. And the process doesn't draw blood, reducing the risk of infections.
Mark Kendall, an Australian biomedical engineer, was part of a team at the University of Queensland that advanced the Nanopatch by vaccinating animals. Now his company, Vaxxas, is on a mission to commercialize the device for human use. He plans to run an international trial using the Nanopatch, starting with the human papilloma virus (HPV) vaccine to protect against cervical cancer.
Mark Kendall | Speaker | TED.com